Frames

The Challenge of Designing Coatings for Biomaterials Applications

(click on a #, the slide will appear in a separate window, you may want to resize the windows to improve the viewing)
(Each slide is about 50K)

Contents:
[01] [02] [03] [04] [05]

Biomaterials, some jargon and some very common examples:
[06] [07] [08]

A condensed, focused biomaterials history:
[09] [10]

Costs, quantities and examples of implants:
[11] [12] [13] [14]

Some examples of implant orthopedics:
[15] [16] [17] [18]

Case example 1:
Total elbow failure:
[19] [20] [21] [22] [23] [24] [25]

Case example 2:
Hip implant failure:
[26] [27] [28] [29]

Case example 3:
Hip implant failure:
[30] [31] [32] [33]

Case example 4:
A compilation of 4 failures of hydroxyapatite (HA) coated materials:
[34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46]

The FDA and "510k":
[47]

Engineered materials in total hip replacement:
[48] [49]

Mechanical properties and bioactive properties of biomaterials:
[50] [51]

Biomaterials R&D through the patent literature:
[52]

53-54 The role of hydroxyapatite coatings:
[53] [54]

Biological response of hydroxyapatite in the body:
[55] [56] [57] [58]

Interface reactions of hydroxyapatite:
[59] [60]

Apatite formation of materials:
[61] [62] [63] [64]

Engineered materials and coating techniques:
[65] [66] [67]

Thermal spray processing and diagnostic methods:
[68] [69] [70] [71] [72] [73]

Thermal spray processing and diagnostic methods:
[74] [75]

Two specific thermal spray applications:
[76]

Hydroxyapatite standards:
[77]

Phase structure and relationships for hydroxyapatite:
[78] [79] [80] [81]

The importance of the feedstock properties:
[82] [83] [84]

Testing of coatings:
[85] [86]

Model of a cooling hydroxyapatite splat:
[87]

Phase measurement in hydroxyapatite:
[88] [89] [90]

Amorphous / crystalline phase control:
[91] [92] [93] [94] [95]

In vitro degradation:
[96] [97]

Process / phase relationship model:
[98]

Critical issues and design issues:
[99] [100] [101] [102] [103]

A summary of biomaterials approaches:
[104]

Summary and conclusions:
[105] [106] [107] [108]


08/06/00

Back to MTL

Back to C. Berndt

Disclaimer: Don't believe everything that you read.